#
Aerobid
  • Treatments
  • Asthma

Aerobid (Inhalation)

Generic name:flunisolide (inhalation route) [ floo-NIS-oh-lide ]
Drug class:Inhaled corticosteroids

Medically reviewed by Drugs.com. Last updated on Apr 23, 2022.

Commonly used brand name(s)

In the U.S.

  • Aerobid
  • Aerobid-M
  • Aerospan

Available Dosage Forms:

  • Aerosol Powder

Therapeutic Class: Anti-Inflammatory

Pharmacologic Class: Adrenal Glucocorticoid

Uses for Aerobid

Flunisolide is used to help control symptoms of asthma and improve lung function. This medicine will not relieve an asthma attack that has already started.

Flunisolide belongs to the family of medicines known as corticosteroids (cortisone-like medicines). It works by preventing inflammation (swelling) in the lungs that causes an asthma attack.

This medicine is available only with your doctor's prescription.

Before using Aerobid

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of inhaled flunisolide in children. However, safety and efficacy have not been established in children younger than 4 years of age, and this medication is not indicated in children younger than 6 years of age.

Geriatric

Although appropriate studies on the relationship of age to the effects of inhaled flunisolide have not been performed in the geriatric population, no geriatric-specific problems have been documented to date. However, elderly patients are more likely to have age-related l...